On March 4th, 2019, Dr. Paul Nghiem received the Eugene J. Van Scott Award for Innovative Therapy and delivered the Philip Frost Leadership lecture in Washington, D.C. He discussed the need to prioritize treatment modalities that are less toxic and more effective for Merkel Cell Carcinoma (MCC). On noting that MCC cases have increased by 95% from 2010 to 2017, Dr. Nghiem addressed three main goals that aim to improve patient care. Preliminary studies highlight that performing wide local excisions pose the risk of increased morbidity and delayed time to radiation treatment. Additionally, patients treated with immunotherapy have shown higher overall survival rates and recurrence free survival in comparison to patients treated with traditional chemotherapy. To implement customized care, a dedicated team of physicians across multiple specialties are best guided by an overseeing dermatologist.
Dr. Paul Nghiem, MD, PhD is the George F. Odland Endowed Chair in Dermatology, Professor & Head of the University of Washington Division of Dermatology and an Affiliate Investigator of the Fred Hutchinson Cancer Research Center.
Full Plenary Lecture Video
“Less toxic, more effective: A win-win for Merkel cell carcinoma patients”
In recognition of this lecture, Dr. Nghiem was awarded the Eugene J. Van Scott Award for Innovative Therapy of the Skin
Lecture Subtopic Videos
Surgery and Local Therapy
Surveillance for Recurrent MCC
Systemic Therapy for Advanced MCC
Role of Dermatologist & Conclusion
To read more about this lecture, please click here.
Download the article
The authoritative source on Merkel cell carcinoma.
May 20, 2020
- What is a Merkel cell?
- What is Merkel cell carcinoma?
- Symptoms & appearance of Merkel cell carcinoma
- Causes of Merkel cell carcinoma
- Surgical excision
- Mohs micrographic surgery
- Radiation therapy
- Complementary & alternative therapies
- Clinical trials
- Adjuvant Avelumab in Merkel Cell Carcinoma Trial